Business
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis and treatment patterns for seborrheic dermatitisNew clinical safety and efficacy data of topical roflumilast in patients with seborrheic dermatitis and psoriasisNew safety and pigmentation data for roflumilast foam in individuals with diverse skin types presented at 19th Annual SOCS Symposium WESTLAKE VILLAGE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced six presentations at the 2023 American Academy of Dermatology (AAD) annual meeting, which will take place in New Orleans from March 17-21, 2023 and an additional poster at the SOCS Symposium on March 16, 2023. Among these will be the presentation of late-breaking clinical data on roflumilast cream 0.15% in patients aged 6 years and older with atopic dermatitis from the pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 Phase 3 trials. “The breadth of our scientific data being presented at AAD underscores Arcutis’ commitment to bring meaningful innovation to immuno-dermatology. We are excited by the acceptance of our late-breaking data from the INTEGUMENT pivotal Phase 3 trials, which build strong evidence for the potential of roflumilast cream as an effective once-daily, steroid-free treatment for atopic dermatitis,” said Patrick Burnett, MD, PhD, FAAD, Chief Medical Officer, Arcutis. “Medical meetings like AAD provide an important opportunity for scientific exchange, and we look forward to sharing these findings, and findings from our other topical roflumilast studies, as well as new survey data in seborrheic dermatitis, with the dermatology community.” Presentation details follow: Late Breaking Data PresentationLate breaking news: Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children aged ≥ 6 With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2)Presenting Author: Dr. Lawrence F. EichenfieldTime: March 18, 2023, 11:00-11:10 am CTRoom: Theater B Poster PresentationsPatient and Healthcare Provider Perspective on the Disease Burden of Seborrheic Dermatitis in the United Stat...